These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29889579)

  • 1. Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control.
    Zahedifard F; Rafati S
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):461-469. PubMed ID: 29889579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian host defense peptides and their implication on combating Leishmania infection.
    Abdossamadi Z; Seyed N; Rafati S
    Cell Immunol; 2016 Nov; 309():23-31. PubMed ID: 27729107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmaniasis and various immunotherapeutic approaches.
    Taslimi Y; Zahedifard F; Rafati S
    Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro leishmanicidal activity of antimicrobial peptide KDEL against Leishmania tarentolae.
    Cao L; Jiang W; Cao S; Zhao P; Liu J; Dong H; Guo Y; Liu Q; Gong P
    Acta Biochim Biophys Sin (Shanghai); 2019 Dec; 51(12):1286-1292. PubMed ID: 31761925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live Leishmania tarentolae secreting HNP1 as an immunotherapeutic tool against Leishmania infection in BALB/c mice.
    Abdossamadi Z; Taheri T; Seyed N; Montakhab-Yeganeh H; Zahedifard F; Taslimi Y; Habibzadeh S; Gholami E; Gharibzadeh S; Rafati S
    Immunotherapy; 2017 Oct; 9(13):1089-1102. PubMed ID: 29032739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and perspectives of the immunotherapy of leishmaniasis.
    El-On J
    Isr Med Assoc J; 2009 Oct; 11(10):623-8. PubMed ID: 20077951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in treatment of leishmaniasis.
    Akbari M; Oryan A; Hatam G
    Immunol Lett; 2021 May; 233():80-86. PubMed ID: 33771555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite.
    Zahedifard F; Lee H; No JH; Salimi M; Seyed N; Asoodeh A; Rafati S
    Exp Parasitol; 2020 Feb; 209():107823. PubMed ID: 31862270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modes of action of Leishmanicidal antimicrobial peptides.
    Marr AK; McGwire BS; McMaster WR
    Future Microbiol; 2012 Sep; 7(9):1047-59. PubMed ID: 22953706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic Potential of Interleukin-32 and Trained Immunity for Leishmaniasis Treatment.
    Teufel LU; Joosten LAB; Dos Santos JC
    Trends Parasitol; 2021 Feb; 37(2):130-141. PubMed ID: 33082090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current approaches to discover marine antileishmanial natural products.
    Tempone AG; Martins de Oliveira C; Berlinck RG
    Planta Med; 2011 Apr; 77(6):572-85. PubMed ID: 21243582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research.
    Elmahallawy EK; Alkhaldi AAM; Saleh AA
    Biomed Pharmacother; 2021 Jul; 139():111671. PubMed ID: 33957562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate immunity against Leishmania infections.
    Gurung P; Kanneganti TD
    Cell Microbiol; 2015 Sep; 17(9):1286-94. PubMed ID: 26249747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present status of antileishmanial vaccines.
    Ghosh M; Bandyopadhyay S
    Mol Cell Biochem; 2003 Nov; 253(1-2):199-205. PubMed ID: 14619970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of antiprotozoal potential of antimicrobial peptides.
    Santos FA; Cruz GS; Vieira FA; Queiroz BRS; Freitas CDT; Mesquita FP; Souza PFN
    Acta Trop; 2022 Dec; 236():106675. PubMed ID: 36057367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmaniasis in humans: drug or vaccine therapy?
    Ghorbani M; Farhoudi R
    Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Anti-Microbial Peptides (AMPs) against
    El-Dirany R; Shahrour H; Dirany Z; Abdel-Sater F; Gonzalez-Gaitano G; Brandenburg K; Martinez de Tejada G; Nguewa PA
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinigerin induces apoptotic like cell death in a caspase independent manner in Leishmania donovani.
    Sardar AH; Das S; Agnihorti S; Kumar M; Ghosh AK; Abhishek K; Kumar A; Purkait B; Ansari MY; Das P
    Exp Parasitol; 2013 Dec; 135(4):715-25. PubMed ID: 24184774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three decades of clinical trials on immunotherapy for human leishmaniases: a systematic review and meta-analysis.
    Mota CA; Oyama J; Souza Terron Monich M; Brustolin AÁ; Perez de Souza JV; Murase LS; Ghiraldi Lopes LD; Silva Santos TD; Vieira Teixeira JJ; Verzignassi Silveira TG
    Immunotherapy; 2021 Jun; 13(8):693-721. PubMed ID: 33853344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.